Based upon revenue generated through June 30, 2024, the Company is increasing its guidance for anticipated total revenue in 2024 to between $275-300 million, compared to the previously provided guidance of between $255-265 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- CSTL Earnings this Week: How Will it Perform?
- Canaccord recommends buying Castle Biosciences on weakness after MolDX news
- Castle MolDX update doesn’t impact current Dx-SCC Medicare coverage, says Baird
- Castle Biosciences downside risk ‘limited’ on MolDx decision, says Leerink
- Castle Biosciences slides after MolDX determination on carcinoma test